NO20040307L - Piperidinderivater som NMDA-reseptorantagonister - Google Patents

Piperidinderivater som NMDA-reseptorantagonister

Info

Publication number: NO20040307L
Authority: NO; Norway
Prior art keywords: sub; alkyl; sup; hydrogen; groups
Prior art date: 2001-07-24

Application number

NO20040307A

Other languages

English (en)

Other versions

NO327099B1 (no

Inventor

Eva Kovacsne Bozo

Gyorgy Domany

Jozsef Nagy

Sandor Farkas

Istvan Borza

Csilla Horvath

Gizella Bartane Szalai

Sandor Kolok

Istvan Vago

Attila Bielik

Gyorgyi Ignaczne Szendrei

Gyorgy Keseru

Original Assignee

Richter Gedeon Vegyeszet

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-24

Filing date

2004-01-23

Publication date

2004-03-23

2001-07-24 Priority claimed from HU0103055A external-priority patent/HU226978B1/hu

2002-07-10 Priority claimed from HU0202213A external-priority patent/HU225905B1/hu

2004-01-23 Application filed by Richter Gedeon Vegyeszet filed Critical Richter Gedeon Vegyeszet

2004-03-23 Publication of NO20040307L publication Critical patent/NO20040307L/no

2009-04-20 Publication of NO327099B1 publication Critical patent/NO327099B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Ophthalmology & Optometry (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
Endocrinology (AREA)
Biochemistry (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
AIDS & HIV (AREA)
Rheumatology (AREA)

NO20040307A 2001-07-24 2004-01-23 Piperidinderivater som NMDA-reseptorantagonister, fremgangsmater for fremstilling av disse, og farmasoytiske preparater inneholdende disse NO327099B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
HU0103055A HU226978B1 (en)	2001-07-24	2001-07-24	New carboxylic acid amide compounds, process for their preparation and pharmaceutical compositions containing them and their use
HU0202213A HU225905B1 (en)	2002-07-10	2002-07-10	Solid-supported parallel synthesis of new carboxylic acid amide derivatives
PCT/HU2002/000071 WO2003010159A1 (en)	2001-07-24	2002-07-23	Piperidine derivatives as nmda receptor antagonists

Publications (2)

Publication Number	Publication Date
NO20040307L true NO20040307L (no)	2004-03-23
NO327099B1 NO327099B1 (no)	2009-04-20

Family

ID=90001553

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20040307A NO327099B1 (no)	2001-07-24	2004-01-23	Piperidinderivater som NMDA-reseptorantagonister, fremgangsmater for fremstilling av disse, og farmasoytiske preparater inneholdende disse

Country Status (32)

Country	Link
US (1)	US7435744B2 (no)
EP (1)	EP1409477B1 (no)
JP (1)	JP4322113B2 (no)
KR (1)	KR100890676B1 (no)
CN (1)	CN100413860C (no)
AT (1)	ATE408611T1 (no)
AU (1)	AU2002313566B2 (no)
BG (1)	BG66441B1 (no)
BR (1)	BR0211393A (no)
CA (1)	CA2453383C (no)
CO (1)	CO5560570A2 (no)
CY (1)	CY1109401T1 (no)
CZ (1)	CZ2004233A3 (no)
DE (1)	DE60228969D1 (no)
DK (1)	DK1409477T3 (no)
EA (1)	EA010162B1 (no)
EE (1)	EE05429B1 (no)
ES (1)	ES2312603T3 (no)
HR (1)	HRP20040178B1 (no)
IL (1)	IL159393A (no)
IS (1)	IS7066A (no)
MX (1)	MXPA04000737A (no)
NO (1)	NO327099B1 (no)
NZ (1)	NZ530055A (no)
PL (1)	PL216636B1 (no)
PT (1)	PT1409477E (no)
RS (1)	RS50767B (no)
SI (1)	SI1409477T1 (no)
SK (1)	SK287726B6 (no)
UA (1)	UA77684C2 (no)
WO (1)	WO2003010159A1 (no)
ZA (1)	ZA200400417B (no)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10210779A1 (de) *	2002-03-12	2003-10-09	Merck Patent Gmbh	Cyclische Amide
PA8575901A1 (es) *	2002-07-18	2004-07-20	Pfizer Prod Inc	Derivados de piperidina novedosos
ES2222833B1 (es) *	2003-07-30	2006-03-01	Laboratorios Del Dr. Esteve, S.A.	Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos.
WO2005023761A2 (en)	2003-09-11	2005-03-17	Kemia, Inc.	Cytokine inhibitors
EP1666464A4 (en) *	2003-09-25	2008-12-10	Shionogi & Co	PIPERIDINE DERIVATIVE HAVING ANTAGONIST ACTIVITY OF THE NDMA RECEPTOR
WO2005039564A1 (en) *	2003-10-02	2005-05-06	Vertex Pharmaceuticals Incorporated	Phthalimide compounds useful as protein kinase inhibitors
HUP0401522A2 (en) *	2004-07-29	2006-04-28	Richter Gedeon Vegyeszet	New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation
HU227000B1 (en) *	2004-07-29	2010-04-28	Richter Gedeon Nyrt	Nmda receptor antagonist benzoyl urea derivatives, and pharmaceutical compositions containing them
EP1988077A4 (en)	2006-02-23	2009-09-02	Shionogi & Co	NUCLEIC HETEROCYCLIC DERIVATIVES SUBSTITUTED BY CYCLIC GROUPS
HUP0600809A3 (en) *	2006-10-27	2008-09-29	Richter Gedeon Nyrt	New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
HUP0600808A3 (en) *	2006-10-27	2008-09-29	Richter Gedeon Nyrt	New benzamide derivatives as bradykinin antagonists, process for their preparation and pharmaceutical compositions containing them
HUP0600810A3 (en) *	2006-10-27	2008-09-29	Richter Gedeon Nyrt	New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
EP1918281A1 (en) *	2006-11-02	2008-05-07	Laboratorios del Dr. Esteve S.A.	Phenylamino-substituted piperidine compounds, their preparation and use as medicaments
WO2008055945A1 (en)	2006-11-09	2008-05-15	Probiodrug Ag	3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
EP2091948B1 (en)	2006-11-30	2012-04-18	Probiodrug AG	Novel inhibitors of glutaminyl cyclase
CN101668525A (zh)	2007-03-01	2010-03-10	前体生物药物股份公司	谷氨酰胺酰环化酶抑制剂的新用途
US9656991B2 (en)	2007-04-18	2017-05-23	Probiodrug Ag	Inhibitors of glutaminyl cyclase
EP2184272A4 (en) *	2007-08-21	2011-11-09	Shionogi & Co	PIPERAZINE DERIVATIVE
DE102007047737A1 (de) *	2007-10-05	2009-04-30	Merck Patent Gmbh	Piperidin- und Piperazinderivate
AU2007360523A1 (en) *	2007-10-27	2009-04-30	Richter Gedeon Nyrt.	New non-peptide derivatives as bradykinin B1 antagonists
US20100010044A1 (en) *	2008-07-08	2010-01-14	Forest Laboratories Holdings Limited	Novel crystalline form of 2-[4-(4-fluoro-benzyl)-piperidine-1-yl]-2-oxo-n-(2-oxo-2,3-dihydro-benzoxazol-6-yl)-acetamide
CN102159077A (zh) *	2008-08-21	2011-08-17	吉瑞工厂	用于治疗神经性疼痛的方法
US20110190348A1 (en) *	2008-08-21	2011-08-04	Pradeep Banerjee	Methods for treating cns disorders
WO2010068794A2 (en)	2008-12-10	2010-06-17	The General Hospital Corporation	Hif inhibitors and use thereof
HUP0900130A3 (en)	2009-03-03	2012-02-28	Richter Gedeon Nyrt	Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation
ES2548913T3 (es)	2009-09-11	2015-10-21	Probiodrug Ag	Derivados heterocíclicos como inhibidores de glutaminil ciclasa
KR20120107993A (ko) *	2009-12-15	2012-10-04	뉴롭, 인코포레이티드	신경계 장애의 치료를 위한 화합물
AU2011216950A1 (en)	2010-02-16	2012-08-23	Pfizer Inc.	(R)-4-((4-((4-(tetrahydrofuran-3-yloxy) benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2H-pyran-4-ol, a partial agonist of 5-HT4 receptors
WO2011107530A2 (en)	2010-03-03	2011-09-09	Probiodrug Ag	Novel inhibitors
CA2789440C (en)	2010-03-10	2020-03-24	Probiodrug Ag	Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
JP5945532B2 (ja)	2010-04-21	2016-07-05	プロビオドルグエージー	グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
HUP1000424A2 (en)	2010-08-11	2012-05-02	Richter Gedeon Nyrt	Use of radiprodil in attention deficit hyperactivity disorder
US8530670B2 (en)	2011-03-16	2013-09-10	Probiodrug Ag	Inhibitors
EP2921481A1 (de) *	2011-12-27	2015-09-23	Bayer Intellectual Property GmbH	4-piperidine carboxylic acid derivatives
EP2838530B1 (en)	2012-04-20	2017-04-05	UCB Biopharma SPRL	Methods for treating parkinson's disease
US9868730B2 (en)	2013-02-18	2018-01-16	The Trustees Of Columbia University In The City Of New York	Kappa opioid receptor selective compounds, compositions, and uses thereof
WO2016073738A2 (en)	2014-11-05	2016-05-12	Flexus Biosciences, Inc.	Immunoregulatory agents
UY36390A (es)	2014-11-05	2016-06-01	Flexus Biosciences Inc	Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
WO2017053769A1 (en) *	2015-09-25	2017-03-30	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Triazole derivatives as p2y14 receptor antagonists
EP3461819B1 (en)	2017-09-29	2020-05-27	Probiodrug AG	Inhibitors of glutaminyl cyclase
ES2897050T3 (es)	2017-12-08	2022-02-28	Boehringer Ingelheim Int	Derivados de imidazopiridina y el uso de los mismos como medicamento
WO2019115586A1 (en) *	2017-12-12	2019-06-20	Phenex Discovery Verwaltungs-GmbH	Oxalamides as modulators of indoleamine 2,3-dioxygenase
CN112888684B (zh) *	2018-10-17	2023-10-10	勃林格殷格翰国际有限公司	4-嘧啶-5-基甲基-吗啉衍生物及其作为药物的用途
MA53898B1 (fr)	2018-10-17	2023-03-31	Boehringer Ingelheim Int	Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation comme médicament
WO2020079042A1 (en)	2018-10-17	2020-04-23	Boehringer Ingelheim International Gmbh	4-pyridinylmethyl-morpholine derivatives and the use thereof as medicament
JP7318015B2 (ja)	2019-06-04	2023-07-31	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	特に抑うつ病性障害の処置のための、ｎｒ２ｂネガティブ調節剤としてのプリン誘導体および医薬としてのその使用
US12398143B2 (en)	2019-06-04	2025-08-26	Boehringer Ingelheim International Gmbh	Imidazopyrazine derivatives and the use thereof as medicament
CN113234036B (zh) *	2021-05-12	2023-07-14	斯莱普泰(上海)生物医药科技有限公司	Nmda受体拮抗剂及其用途
CA3228004A1 (en)	2021-08-06	2023-02-09	Marie Genin	Formulations of radiprodil
CN114163388A (zh) *	2021-12-15	2022-03-11	陕西汉江药业集团股份有限公司	芬苯达唑中的杂质i、杂质ⅱ和杂质ⅲ的制备方法
WO2025137652A2 (en)	2023-12-20	2025-06-26	Grin Therapeutics, Inc.	Methods of using radiprodil in the treatment of disorders

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE254999C (no)
US2324123A (en)	1941-07-08	1943-07-13	Eastman Kodak Co	Fog inhibitor for photographic developers
US3260723A (en)	1963-08-27	1966-07-12	Parke Davis & Co	4-phenoxy piperidines; alpha4-phenoxy piperideines
NL6501323A (no)	1965-02-02	1966-08-03
US3632767A (en)	1968-02-12	1972-01-04	Mallinckrodt Chemical Works	Treatment of depression with 4-substituted piperidines
AU639529B2 (en)	1987-03-04	1993-07-29	Higuchi, Yoshinari	Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives
SK232890A3 (en)	1989-05-17	1998-11-04	Pfizer	2-piperidino and 2-pyrrolidino-1-alkanols derivatives and preparation method thereof
FR2672286B1 (fr) *	1991-01-31	1994-11-18	Synthelabo	Derives de 1-(4-chlorophenyl)-2-[4-(phenylmethyl)piperidin-1-yl]ethanol, leur preparation et leur application en therapeutique.
US5436255A (en)	1992-07-23	1995-07-25	Pfizer Inc.	Method of treating diseases susceptable to treatment by blocking NMDA-receptors
TW281670B (no) *	1993-09-02	1996-07-21	Hoffmann La Roche
ZA9610736B (en)	1995-12-22	1997-06-27	Warner Lambert Co	2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610745B (en) *	1995-12-22	1997-06-24	Warner Lambert Co	4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610738B (en)	1995-12-22	1997-06-24	Warner Lambert Co	Subtype selective nmda receptor ligands and the use thereof
ZA9610741B (en)	1995-12-22	1997-06-24	Warner Lambert Co	4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
WO1997023202A1 (en)	1995-12-22	1997-07-03	STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITYA ND THE UNIVERSITY OF OREGON, EUGENE OREGON	Subtype-selective nmda receptor ligands and the use thereof
TW498067B (en) *	1996-07-19	2002-08-11	Hoffmann La Roche	4-hydroxy-piperidine derivatives
DE19643790A1 (de)	1996-10-30	1998-05-07	Merck Patent Gmbh	Benzoxazol-Derivat
US6048900A (en) *	1998-02-13	2000-04-11	Bayer Corporation	Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
JP2000510870A (ja) *	1997-02-14	2000-08-22	バイエル・コーポレーシヨン	Ｎｐｙ５受容体アンタゴニストとしてのアミド類
KR20010024548A (ko)	1997-10-24	2001-03-26	로즈 암스트롱	질병관련 또는 약물유발 운동장해의 치료방법
PE20000728A1 (es)	1998-06-26	2000-08-21	Cocensys Inc	Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
WO2000025109A1 (en)	1998-10-28	2000-05-04	Scofield Dillon F	Electrodynamic particle size analyzer
US6399631B1 (en) *	1999-07-23	2002-06-04	Pfizer Inc.	Carbazole neuropeptide Y5 antagonists
US6369076B1 (en)	1999-10-29	2002-04-09	Merck & Co. Inc.	5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
US6291499B1 (en)	1999-10-29	2001-09-18	Merck & Co., Inc.	2-cyclohexyl benzimidazole NMDA/NR2B antagonists
AU1153601A (en)	1999-10-29	2001-05-08	Merck Sharp & Dohme Limited	Method to treat pain utilizing benzimidazole NMDA NR2B antagonists
US6432976B1 (en)	1999-10-29	2002-08-13	Merck & Co., Inc.	8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
US6316474B1 (en)	1999-10-29	2001-11-13	Merck & Co., Inc.	2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
US6489477B1 (en)	1999-10-29	2002-12-03	Merck & Co., Inc.	2-aza-bicyclo[2.2.2]octane NMDA/NR2B antigonists
US6476041B1 (en)	1999-10-29	2002-11-05	Merck & Co., Inc.	1,4 substituted piperidinyl NMDA/NR2B antagonists

2002
- 2002-07-23 SI SI200230752T patent/SI1409477T1/sl unknown
- 2002-07-23 PL PL367259A patent/PL216636B1/pl unknown
- 2002-07-23 EE EEP200400058A patent/EE05429B1/xx unknown
- 2002-07-23 RS YUP-1039/03A patent/RS50767B/sr unknown
- 2002-07-23 EP EP02753161A patent/EP1409477B1/en not_active Expired - Lifetime
- 2002-07-23 DK DK02753161T patent/DK1409477T3/da active
- 2002-07-23 EA EA200400213A patent/EA010162B1/ru not_active IP Right Cessation
- 2002-07-23 CN CNB028142349A patent/CN100413860C/zh not_active Expired - Lifetime
- 2002-07-23 PT PT02753161T patent/PT1409477E/pt unknown
- 2002-07-23 CZ CZ2004233A patent/CZ2004233A3/cs unknown
- 2002-07-23 WO PCT/HU2002/000071 patent/WO2003010159A1/en not_active Ceased
- 2002-07-23 AU AU2002313566A patent/AU2002313566B2/en not_active Expired
- 2002-07-23 SK SK102-2004A patent/SK287726B6/sk not_active IP Right Cessation
- 2002-07-23 DE DE60228969T patent/DE60228969D1/de not_active Expired - Lifetime
- 2002-07-23 MX MXPA04000737A patent/MXPA04000737A/es active IP Right Grant
- 2002-07-23 BR BR0211393-7A patent/BR0211393A/pt not_active IP Right Cessation
- 2002-07-23 CA CA2453383A patent/CA2453383C/en not_active Expired - Lifetime
- 2002-07-23 JP JP2003515518A patent/JP4322113B2/ja not_active Expired - Lifetime
- 2002-07-23 HR HRP20040178AA patent/HRP20040178B1/hr not_active IP Right Cessation
- 2002-07-23 AT AT02753161T patent/ATE408611T1/de active
- 2002-07-23 KR KR1020047001042A patent/KR100890676B1/ko not_active Expired - Fee Related
- 2002-07-23 ES ES02753161T patent/ES2312603T3/es not_active Expired - Lifetime
- 2002-07-23 IL IL159393A patent/IL159393A/en active IP Right Grant
- 2002-07-23 NZ NZ530055A patent/NZ530055A/en not_active IP Right Cessation
2003
- 2003-12-05 IS IS7066A patent/IS7066A/is unknown
2004
- 2004-01-20 UA UA2004021342A patent/UA77684C2/uk unknown
- 2004-01-20 ZA ZA2004/00417A patent/ZA200400417B/en unknown
- 2004-01-21 US US10/761,940 patent/US7435744B2/en not_active Expired - Lifetime
- 2004-01-23 NO NO20040307A patent/NO327099B1/no not_active IP Right Cessation
- 2004-02-20 BG BG108592A patent/BG66441B1/bg unknown
- 2004-02-23 CO CO04015496A patent/CO5560570A2/es active IP Right Grant
2008
- 2008-12-03 CY CY20081101405T patent/CY1109401T1/el unknown

Also Published As

Publication number	Publication date
EA200400213A1 (ru)	2004-08-26
BR0211393A (pt)	2004-08-17
KR20040041152A (ko)	2004-05-14
US20040157886A1 (en)	2004-08-12
CO5560570A2 (es)	2005-09-30
JP2005515968A (ja)	2005-06-02
CA2453383C (en)	2010-04-06
PT1409477E (pt)	2008-11-20
KR100890676B1 (ko)	2009-03-26
CN100413860C (zh)	2008-08-27
IS7066A (is)	2003-12-05
DE60228969D1 (no)	2008-10-30
BG66441B1 (bg)	2014-08-29
EE200400058A (et)	2004-04-15
RS50767B (sr)	2010-08-31
WO2003010159A1 (en)	2003-02-06
PL216636B1 (pl)	2014-04-30
JP4322113B2 (ja)	2009-08-26
NO327099B1 (no)	2009-04-20
US7435744B2 (en)	2008-10-14
SI1409477T1 (sl)	2009-02-28
UA77684C2 (en)	2007-01-15
ATE408611T1 (de)	2008-10-15
RS103903A (sr)	2007-02-05
SK1022004A3 (en)	2004-07-07
AU2002313566B8 (en)	2003-02-18
DK1409477T3 (da)	2008-12-08
HRP20040178B1 (hr)	2013-05-31
NZ530055A (en)	2005-07-29
CA2453383A1 (en)	2003-02-06
PL367259A1 (en)	2005-02-21
MXPA04000737A (es)	2004-07-08
IL159393A0 (en)	2004-06-01
EP1409477B1 (en)	2008-09-17
ES2312603T3 (es)	2009-03-01
ZA200400417B (en)	2005-07-27
CZ2004233A3 (cs)	2004-12-15
HK1063464A1 (en)	2004-12-31
HRP20040178A2 (en)	2005-04-30
EA010162B1 (ru)	2008-06-30
WO2003010159A8 (en)	2004-02-12
CN1556805A (zh)	2004-12-22
EE05429B1 (et)	2011-06-15
AU2002313566B2 (en)	2007-05-24
SK287726B6 (en)	2011-07-06
EP1409477A1 (en)	2004-04-21
BG108592A (bg)	2005-03-31
IL159393A (en)	2011-01-31
CY1109401T1 (el)	2014-07-02

Publication	Publication Date	Title
NO20040307L (no)	2004-03-23	Piperidinderivater som NMDA-reseptorantagonister
NO970501L (no)	1997-08-06	Substituerte kinazolinderivater
HRP20080226T3 (en)	2008-06-30	Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
NO20101069L (no)	2001-09-06	Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva
EA199901102A1 (ru)	2000-08-28	Производные азетидинилпропилпиперидина, промежуточные соединения и применение в качестве антагонистов тахикинина
NZ503912A (en)	2002-09-27	Piperidinylaminomethyl trifluoromethyl cyclic ether compounds and their use as substance P antagonists
NO20013684L (no)	2001-09-28	Substituerte fenetylaminderivater
EA199800170A1 (ru)	1998-08-27	Производные 2-(4-замещенного)бензиламино-2-метилпропанамида
DK0759027T3 (da)	2000-03-27	Bicykliske amidinderivater som inhibitorer af nitrogenoxidsynthetase
DE69231445D1 (de)	2000-10-19	Triazole enthaltende antifungizide mittel
DE69401716D1 (de)	1997-03-20	Imidazo [1,2-a] pyrasin-4-on-derivate welche als ampa und nmda receptor antagonisten dienen
AUPP150098A0 (en)	1998-02-19	Benzamide derivatives
TR200000725T2 (tr)	2000-08-21	Bir monoamin oksidaz inhibitörü ve h5-HT1B antagonistinin bileşimi
PT1044186E (pt)	2006-07-31	Composto 2-benzilamino-2-fenil-acetamida substituidos
BR0213731A (pt)	2004-10-19	Compostos de silìcio
CA2210913A1 (en)	1996-08-08	Antipsychotic 4-(1h-indolyl-1-yl)-1-substituted piperidine derivatives
DK0902018T3 (da)	2008-10-20	2-(arylpheny)amino-imidazolinderivater
ATE270289T1 (de)	2004-07-15	Heteroaryloxypropanolamine als beta3- adrenergischer rezeptor-agonisten
ATE172454T1 (de)	1998-11-15	Pyridazinon derivate mit pharmazeutischer wirkung
CA2285535A1 (en)	1998-11-12	Benzimidazole derivative for treating allergy-related disease
DE60213087D1 (de)	2006-08-24	Pyrimidin-derivate als selektive inhibitoren von cox-2
BR0016517A (pt)	2002-09-17	Derivados diacila de diamina de propileno herbicidas
DE60106421D1 (de)	2004-11-18	Hydrate und kristalle einer neuraminsäureverbindung
DE59604901D1 (de)	2000-05-11	Carbamoylcarbonsäureamide
EA200400758A1 (ru)	2005-06-30	Новые соединения бензотиазина и бензотиадиазина, способ их получения и фармацевтические композиции, которые их содержат

Legal Events

Date	Code	Title	Description
2013-05-21	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: RICHTER GEDEON NYRT, HU
2014-06-23	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: UCB PHARMA SA, BE
2022-08-15	MK1K	Patent expired